Novel Drug Delivery Systems Market Outlook:
Novel Drug Delivery Systems Market size was valued at USD 145.1 billion in 2025 and is projected to reach USD 240.65 billion by the end of 2035, rising at a CAGR of 5.70% during the forecast period, i.e., 2026–2035. In 2026, the industry size of novel drug delivery systems is estimated at USD 152.91 billion.
In world pharmaceutical markets, the patient pool for products assisted by novel drug delivery systems primarily includes patients with chronic and high-prevalence diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. The Doctoral research and clinical or research trial information published in the National Institute of Health shows a large increase in trials involving drug delivery. Demand is further supported by patient populations needing better efficacy, compliance, and controlled release formulations. Import/export flows are crucial. The vast majority of APIs for the U.S. market are produced outside the U.S., and finished dosage forms depend on intermediates and assembly components that are imported.
The novel drug delivery systems (NDDS) market is rapidly evolving, driven by advances in technology, greater patient demand for targeted and effective therapies, and shifting healthcare needs. Nanotechnology is increasingly used to create nanoparticles, nanocarriers, and liposomes for the purpose of drug delivery. This technology often improves drug selection through the enhancement of bioavailability and targeting of drugs. This advancing technology aligns with the increasing demand for biologics and biopharmaceuticals, particularly in the NDDS market development of delivery systems that are able to accommodate the complexity of large and fragile biologic molecules. The NDDS market appears to be promoting biopharmaceutical development in hospitals, academia, and business, particularly in the realm of oncology and immunotherapy.
